Xeris Biopharma (NASDAQ:XERS – Get Free Report) and AleAnna (NASDAQ:ANNA – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, profitability, dividends, valuation and institutional ownership.
Insider and Institutional Ownership
42.8% of Xeris Biopharma shares are owned by institutional investors. Comparatively, 38.1% of AleAnna shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by company insiders. Comparatively, 42.9% of AleAnna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Profitability
This table compares Xeris Biopharma and AleAnna’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Xeris Biopharma | -5.88% | N/A | -4.66% |
| AleAnna | -46.01% | -14.90% | -8.74% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Xeris Biopharma | $203.07 million | 5.00 | -$54.84 million | ($0.10) | -61.20 |
| AleAnna | $1.42 million | 133.77 | -$12.34 million | $0.04 | 71.25 |
AleAnna has lower revenue, but higher earnings than Xeris Biopharma. Xeris Biopharma is trading at a lower price-to-earnings ratio than AleAnna, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of current recommendations for Xeris Biopharma and AleAnna, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Xeris Biopharma | 1 | 2 | 5 | 0 | 2.50 |
| AleAnna | 1 | 0 | 0 | 0 | 1.00 |
Xeris Biopharma currently has a consensus target price of $10.08, suggesting a potential upside of 64.76%. Given Xeris Biopharma’s stronger consensus rating and higher possible upside, equities analysts plainly believe Xeris Biopharma is more favorable than AleAnna.
Summary
Xeris Biopharma beats AleAnna on 8 of the 13 factors compared between the two stocks.
About Xeris Biopharma
Xeris Biopharma Holdings, Inc., a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.
About AleAnna
AleAnna, Inc. engages in oil and gas exploration and production activities. It focuses on Italy’s natural gas reserves and developing renewable energy solutions. The company was founded in 2007 and is headquartered in Dallas, TX.
Receive News & Ratings for Xeris Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xeris Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
